Jaguar Health Inc Dossier - Source-backed chat

Jaguar Health Inc

JAGXNASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.95Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $2.1M

Enterprise Value $28M

Shares Outstanding 434.1K diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Jaguar Health is undergoing a significant business model transition in 2026, shifting from direct commercialization to a development-focused model funded by non-dilutive licensing agreements. The company's Q1 2026 financial turnaround, driven by the Woodward/Future Pak licensing deal, has dramatically improved short-term operating metrics. However, long-term viability remains heavily dependent on the clinical and regulatory success of its pipeline assets, particularly crofelemer for rare pediatric intestinal failure indications (MVID and SBS-IF). While the non-dilutive funding reduces immediate dilution risks, the company's historical cash burn and complex capital structure warrant a cautious Hold stance until clinical milestones are achieved.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Clinical trials for MVID or SBS-IF experience delays or fail to meet primary endpoints, pushing back the NDA timeline past 2027. The company's cash burn accelerates, requiring dilutive equity financing. Woodward's commercialization of Mytesi underperforms, limiting future milestone payments and royalty potential.

Base CaseCentral scenario

The company successfully leverages the non-dilutive capital from the Woodward/Future Pak licensing deal to advance its rare disease pipeline. The liquid oral crofelemer formulation achieves positive clinical data in the MVID trial, supporting a planned NDA filing in mid-2027. Nasdaq compliance is maintained following the April 2026 reverse stock split, and operating expenses remain controlled.

Bull CaseUpside scenario

The bull case for Jaguar Health centers on the successful clinical development and regulatory approval of its highly concentrated liquid formulation of crofelemer for rare pediatric intestinal failure indications, specifically microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF). Positive clinical data from its ongoing trials—which have shown up to a 37% reduction in parenteral support for MVID patients—could unlock breakthrough therapy designations in the US and PRIME designation in the EU, paving the way for a New Drug Application (NDA) filing in the first half of 2027. This rare-disease pipeline targets a multi-billion dollar global market and is supported by non-dilutive capital, including an $18 million upfront payment from its January 2026 U.S. licensing agreement with Future Pak for its commercialized products Mytesi and Canalevia-CA1.

Scenarios reflect our research view at the research date.

Key Investment Merits

Substantial non-dilutive funding of up to $38 million from the Woodward/Future Pak licensing agreement, including an $18 million upfront payment.
Strategic pivot allows management to focus resources entirely on high-value rare disease clinical development.
Established safety profile of crofelemer, which has been used in tens of thousands of patients commercially.
Orphan drug designations for MVID and SBS-IF provide potential for market exclusivity and regulatory incentives.

Key Investment Risks

High dependence on a single active pharmaceutical ingredient (crofelemer) for the entire pipeline.
History of substantial net losses and going concern doubts raised by auditors.
Regulatory risks associated with the approval of liquid oral crofelemer for pediatric rare diseases.
Complex capital structure with outstanding debt, royalty obligations, and preferred shares.

Thesis Invalidation Triggers

Failure to file the NDA for crofelemer in MVID by the end of 2027.
Inability to maintain Nasdaq listing requirements, leading to delisting.
Termination or material amendment of the Woodward/Future Pak licensing agreement.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.